Drug profile · INN
herpes zoster vaccine (recombinant, adjuvanted)
SHINGRIX
herpes zoster vaccine (recombinant, adjuvanted) (SHINGRIX) is a envelope glycoprotein e vaccine antigen.
EMA: approved Antiinfectives for systemic use (J07) J07BK03
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — herpes zoster vaccine (recombinant, adjuvanted)
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
herpes zoster vaccine (recombinant, adjuvanted) (SHINGRIX) is a envelope glycoprotein e vaccine antigen.
Key facts
INN herpes zoster vaccine (recombinant, adjuvanted)
Brand SHINGRIX
Mechanism Envelope glycoprotein E vaccine antigen
Target Envelope glycoprotein E
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BK03
Mechanism of action
Envelope glycoprotein E vaccine antigen
Primary target: Envelope glycoprotein E
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is herpes zoster vaccine (recombinant, adjuvanted)?
herpes zoster vaccine (recombinant, adjuvanted) (SHINGRIX) is a envelope glycoprotein e vaccine antigen.
What is the brand name for herpes zoster vaccine (recombinant, adjuvanted)?
SHINGRIX is a marketed brand name for herpes zoster vaccine (recombinant, adjuvanted). Check FDA Drugs@FDA for the current US label holder and prescribing information.